Market evolution: Medical instruments and appliances (CN 9018) — 2015–2025

Introduction

This report analyses the evolution of European Union trade in medical instruments and appliances (Combined Nomenclature code 9018) with the rest of the world over the period 2015 to 2025. The sector, encompassing everything from syringes and catheters to MRI scanners and electro-diagnostic equipment, exhibits robust growth and structural change. The EU has consistently maintained a positive trade balance, acting as a net exporter. However, this period has been characterised by faster growth in imports, increasing specialisation within the bloc, and significant shifts in key trading relationships, all underpinned by a strong post-2020 acceleration in production and value.

1. Strong and accelerating growth in trade value, driven by rising unit values and advanced product segments

The EU's trade in medical instruments expanded substantially over the decade, with both exports and imports growing faster than the global average for many goods. The expansion was not merely volumetric but was significantly powered by increasing unit values, pointing to a shift towards higher-value products.

Exports grew faster than imports in value terms, preserving a healthy trade surplus.

Between 2015 and 2025, the value of EU exports of CN 9018 products rose by 71.6%, from €20.8 billion to €35.6 billion. Imports grew even faster in percentage terms, by 79.6%, from €15.8 billion to €28.3 billion (General Overview). Despite the faster import growth, the EU's trade surplus expanded from €5.0 billion in 2015 to €7.3 billion in 2025, indicating the bloc's strong competitive position.

The price premium for EU exports widened significantly, highlighting a shift to higher-value goods.

A key trend is the divergence in average unit prices. EU export prices (EUR per tonne) increased by 36.4% over the period, reaching €129,236 per tonne in 2025. Import prices rose by 34.5% to €81,271 per tonne. Consequently, the price premium for EU exports over imports grew, with EU exports being nearly 60% more expensive per tonne in 2025. This suggests a growing specialisation in more sophisticated, higher-margin medical technology.

Source: General Overview

Growth was particularly strong in advanced diagnostics and high-value surgical instruments.

The product breakdown reveals where growth was concentrated. The category "Electro-diagnostic apparatus..." (901819) saw explosive growth in import value, increasing from €0.9 billion in 2015 to €4.1 billion in 2025 (+341%). This is likely linked to the expansion of complex diagnostic and monitoring equipment. Similarly, imports of "Needles, catheters, cannulae..." (901839) and "Syringes" (901831) grew strongly. On the export side, "Instruments and appliances... n.e.s." (901890) remained the largest segment, growing by 85% in value, while exports of "Electro-diagnostic apparatus..." (901819) more than doubled (Product Segment Breakdown).

2. Shifting global partnerships and internal specialisation redefine the EU's trade ecosystem

The geography of EU medical device trade underwent notable changes, with import sourcing becoming more diversified while export concentration increased slightly. Within the EU, production and specialisation became more pronounced in a handful of member states.

The United States remains the dominant partner, but Chinese imports have surged.

The United States is the EU's largest partner by a wide margin for both exports and imports. EU exports to the US nearly doubled, reaching €12.2 billion in 2025. However, the most dramatic shift occurred with China. Imports from China grew by 191.5% from €1.0 billion to €2.9 billion, making it the second-largest source of imports behind the US. This reflects China's growing role as a manufacturing base for medical consumables and mid-tech equipment. The UK, post-Brexit, saw modest 13% growth in exports from the EU (General Overview).

Specialisation within the EU intensified, with Ireland and the Netherlands leading.

Analysis of revealed comparative advantage for 2025 shows pronounced specialisation. Ireland (RCA of 5.32) and the Netherlands (RCA of 1.99) are the most specialised EU exporters in this sector, indicating strong competitive advantages. Ireland's specialisation is particularly notable given its smaller total export share. In contrast, countries like Croatia, Luxembourg, and Greece show significant negative specialisation, meaning their medical instrument exports are much smaller than their overall export profile would suggest (Market Structure).

EU production value expanded dramatically, outpacing volume growth.

The value of EU production (measured in EUR) increased by 253% over the available period, reaching €29 billion by 2025. In contrast, production volume (in number of items) grew by only 12.6%. This massive inflation in production value relative to volume underscores the sector's move up the value chain towards more sophisticated and expensive devices, mirroring the trend seen in trade prices (Market Structure).

3. Post-2020 acceleration and increasing trade openness mark the latter half of the decade

The period following 2020 was marked by accelerated activity, likely influenced by the COVID-19 pandemic and subsequent healthcare investment. The sector also demonstrated high trade intensity and an increasing orientation towards export markets.

The period from 2020 onwards saw a marked acceleration in trade and production growth.

The data shows a clear inflection point around 2020-2021. For instance, the value of imports for the "Electro-diagnostic apparatus..." segment (901819) jumped from €1.9 billion in 2019 to €2.1 billion in 2020 and continued surging thereafter. This coincides with global demand spikes for medical equipment during the pandemic. EU production value followed a similar, albeit steeper, acceleration trajectory post-2020.

The EU's trade intensity and export propensity increased significantly.

Trade intensity—the ratio of total trade to production—rose from 86.6% in 2015 to 110.1% in 2025. More notably, export propensity (exports as a percentage of production) jumped from 79.0% to 119.6%. This indicates that the EU medical device sector has become fundamentally more export-oriented, with a growing share of its elevated production destined for global markets (Autonomy & Vulnerability).

Import sourcing became more diversified, while export concentration saw a slight increase.

The Herfindahl-Hirschman Index (HHI) for imports fell from 2383 to 1833, indicating reduced concentration and more diversified sourcing. In contrast, the HHI for exports rose slightly from 1202 to 1431, suggesting a modest increase in export market concentration. This combination points to a strategic recalibration: seeking more diverse supply chains for inputs while potentially focusing sales efforts on fewer, larger destination markets (General Overview).

Conclusion

Over the 2015–2025 period, the EU's medical instruments sector (CN 9018) demonstrated robust health and strategic evolution. It solidified its position as a major global exporter, achieving strong value growth driven by a premium pricing strategy and a pivot towards advanced, high-value segments like electro-diagnostics. The trading landscape shifted notably, with China emerging as a critical import source, while intra-EU specialisation deepened, concentrating competitive advantages in member states like Ireland and the Netherlands. The post-2020 years acted as a catalyst, accelerating growth, boosting production values, and increasing the sector's global orientation, as evidenced by rising export propensity. While the EU maintained a healthy trade surplus, the faster growth in imports highlights an increasing dependency on external supply chains, balanced by a concurrent diversification of import sources. The sector's trajectory is one of increasing sophistication, value-addition, and global integration.